Molecular docking study of anti-breast cancer drugs and Tyrosine kinase receptors with focus on reducing hair loss

  • سال انتشار: 1399
  • محل انتشار: بیست و یکمین کنگره ملی و نهمین کنگره بین المللی زیست شناسی ایران
  • کد COI اختصاصی: BIOCONF21_0751
  • زبان مقاله: انگلیسی
  • تعداد مشاهده: 230
دانلود فایل این مقاله

نویسندگان

Akram Jahangir Khan

Graduate student, Department of Basic Sciences (Biology), Payame Noor University, Tehran,

Zulfiqar Lotfi

Assistant Professor, Department of Basic Sciences (Biology), Payame Noor University, Tehran

Safyeh Soufian

Assistant Professor, Department of Basic Sciences (Biology), Payame Noor University, Arak

چکیده

Tyrosine kinase inhibitors are one of the most effective treatments for breast cancer. Chemotherapy-induced alopecia is a common and unavoidable side effect of breast cancer protocols. The unpleasantness of this condition causes impairment in quality of life, with a lot of psychological burdens and negative impact on self-image as some patients refuse chemotherapy. This study evaluated interactions between tyrosine kinase receptors, anti-breast cancer compounds, and hair follicles. The end goal is to identify drugs with lesser hair loss side effects. Docking was performed between ligands of ۵۲ drugs (FDA-approved) against ۸۰ tyrosine kinase receptors. Auto Dock Vina and Auto Dock tools were utilized for docking. After analyzing results of molecular docking, we selected ۱۰ compounds. After docking between the selected compounds against ۴۸ follicular targets, results were evaluated with Ligplot++ and Discovery Studio software. Fostamatinib and Regorafenib were selected with promising high binding energies against all ۸۰ tyrosine kinase proteins and low binding energy against ۴۸ hair follicle targets. Analysis of the results showed that reduction of Hydrogen bonds leads to minimum energy of drugs and reduces hair loss. It seems that the design and optimization of these two compounds could lead to discovery of a new generation of breast cancer drugs with reduced hair loss in the future.

کلیدواژه ها

Drug design, Hair Follicle, Cancer, Molecular modelling

مقالات مرتبط جدید

اطلاعات بیشتر در مورد COI

COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.

کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.